191 related articles for article (PubMed ID: 36515247)
21. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy.
Bongiovanni D; Schreiner N; Gosetti R; Mayer K; Angiolillo DJ; Sibbing D; Holdenrieder S; Anetsberger A; von Scheidt M; Schunkert H; Laugwitz KL; Schüpke S; Kastrati A; Fegers-Wustrow I; Bernlochner I
Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):e83-e93. PubMed ID: 36546322
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
[TBL] [Abstract][Full Text] [Related]
23. Ticagrelor versus prasugrel in patients with acute myocardial infarction.
Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
Int J Cardiol; 2021 Dec; 344():25-30. PubMed ID: 34619265
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study.
Belviso N; Aronow HD; Wyss R; Barbour M; Zhang Y; Wen X; Kogut S
Pharmacotherapy; 2021 Jun; 41(6):515-525. PubMed ID: 33932252
[TBL] [Abstract][Full Text] [Related]
25. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.
Schulz S; Angiolillo DJ; Antoniucci D; Bernlochner I; Hamm C; Jaitner J; Laugwitz KL; Mayer K; von Merzljak B; Morath T; Neumann FJ; Richardt G; Ruf J; Schömig G; Schühlen H; Schunkert H; Kastrati A;
J Cardiovasc Transl Res; 2014 Feb; 7(1):91-100. PubMed ID: 24371012
[TBL] [Abstract][Full Text] [Related]
26. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
[TBL] [Abstract][Full Text] [Related]
27. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention.
Ahn KT; Seong SW; Choi UL; Jin SA; Kim JH; Lee JH; Choi SW; Jeong MH; Chae SC; Kim YJ; Kim CJ; Kim HS; Cho MC; Gwon HC; Jeong JO; Seong IW;
Medicine (Baltimore); 2019 Mar; 98(11):e14833. PubMed ID: 30882670
[TBL] [Abstract][Full Text] [Related]
29. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI.
Conrotto F; Bertaina M; Raposeiras-Roubin S; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Quadri G; Varbella F; Caneiro Queija B; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Abu-Assi E; D'Ascenzo F
Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):536-542. PubMed ID: 30270638
[TBL] [Abstract][Full Text] [Related]
30. Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial.
Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
Eur Heart J Acute Cardiovasc Care; 2021 Dec; 10(10):1117-1124. PubMed ID: 34468709
[TBL] [Abstract][Full Text] [Related]
31. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
32. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.
Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C
J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388
[TBL] [Abstract][Full Text] [Related]
33. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
34. Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention.
Koshy AN; Giustino G; Sartori S; Kyaw H; Yadav M; Zhang Z; Hooda A; Farooq A; Krishnamoorthy P; Sweeny JM; Khera S; Serrao GW; Sharma R; Suleman J; Dangas G; Kini AS; Mehran R; Sharma SK
JACC Cardiovasc Interv; 2022 Nov; 15(22):2270-2280. PubMed ID: 36423970
[TBL] [Abstract][Full Text] [Related]
35. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
[TBL] [Abstract][Full Text] [Related]
37. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Venetsanos D; Träff E; Erlinge D; Hagström E; Nilsson J; Desta L; Lindahl B; Mellbin L; Omerovic E; Szummer KE; Zwackman S; Jernberg T; Alfredsson J
Heart; 2021 Jul; 107(14):1145-1151. PubMed ID: 33712510
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.
Bergmark BA; Bhatt DL; Steg PG; Budaj A; Storey RF; Gurmu Y; Kuder JF; Im K; Magnani G; Oude Ophuis T; Hamm C; Špinar J; Kiss RG; Van de Werf FJ; Montalescot G; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
J Am Heart Assoc; 2021 Sep; 10(17):e020446. PubMed ID: 34423649
[TBL] [Abstract][Full Text] [Related]
39. Comparative Efficacy and Safety of Oral P2Y
Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
[TBL] [Abstract][Full Text] [Related]
40. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
